Tirzepatide is a novel, dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company. It belongs to a class of medications known as incretin mimetics, which work by mimicking the action of naturally occurring incretin hormones to enhance glucose-dependent insulin secretion and suppress glucagon release.